Clinical Trials Browser

Leukemia, Plasma Cell × Bortezomib × Clear all

NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Phase 1 Completed

Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase 1 Withdrawn

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT00307086 2017-03-06

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

Phase 2 Completed

30 enrolled 7 charts

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT01328236 2011-09-22

Bortezomib

Phase 2 Unknown

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma